Assessment of flonoltinib maleate versus ruxolitinib phosphate in intermediate- to high-risk myelofibrosis (FMF-02): study protocol for a multicenter, randomized, open-label phase IIB trial
- DOI
- 10.1177/20406207261424845
- Published
- 2026-03
- Container
- Therapeutic Advances in Hematology
- Publisher
- SAGE Publications
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1177/20406207261424845,
title = {Assessment of flonoltinib maleate versus ruxolitinib phosphate in intermediate- to high-risk myelofibrosis (FMF-02): study protocol for a multicenter, randomized, open-label phase IIB trial},
author = {Linyu Yang and Ke Tan and Rui Liang and Wei Zhang and Yiqun Wang and Lijuan Chen},
year = {2026},
journal = {Therapeutic Advances in Hematology},
doi = {10.1177/20406207261424845},
url = {https://doi.org/10.1177/20406207261424845}
}RIS
TY - JOUR TI - Assessment of flonoltinib maleate versus ruxolitinib phosphate in intermediate- to high-risk myelofibrosis (FMF-02): study protocol for a multicenter, randomized, open-label phase IIB trial AU - Linyu Yang AU - Ke Tan AU - Rui Liang AU - Wei Zhang AU - Yiqun Wang AU - Lijuan Chen PY - 2026 JO - Therapeutic Advances in Hematology DO - 10.1177/20406207261424845 UR - https://doi.org/10.1177/20406207261424845 ER -
APA
Yang, L., Tan, K., Liang, R., Zhang, W., Wang, Y., & Chen, L. (2026). Assessment of flonoltinib maleate versus ruxolitinib phosphate in intermediate- to high-risk myelofibrosis (FMF-02): study protocol for a multicenter, randomized, open-label phase IIB trial. Therapeutic Advances in Hematology. https://doi.org/10.1177/20406207261424845
Source records
- crossref · retrieved 2026-11-10T20:04:54.221Z